PRESS RELEASE - January 29, 2025 - 2:00 pm CET - Montpellier, France - Euronext Paris: MEDCL

UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization

Medincell's partner Teva Pharmaceuticals shared today the following information:

About UZEDY®

- 2024 sales: $117 million with $43 million in Q4
  - + 17% compared to $100 million updated Teva outlook in November 2024

Q1	Q2	Q3	Q4
$40 million		**$35 million**	**$43 million**

- Initial 2025 Teva outlook: $160 million
  - vs. initial 2024 Teva outlook: $80 million

Medincell receives mid- to high-single digit royalties on all sales and is eligible for $105 million of commercial milestones.

About Olanzapine Long-Acting Injectable (TEV-749 / mdc-TJK)

- Preparation for Filing and Launch
  - Last patient, last visit of Phase 3 pivotal trial expected imminently
  - Long term full safety released data anticipated in Q2 2025
  - NDA* submission anticipated in H2 2025

Teva 2024 Results press release:
https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Teva-Delivers-Second-Consecutive-Year-of-Growth-Announces-Strong-Financial-Results-in-Fourth-Quarter-and-Full-Year-2024-Led-by-Generics-Performance-and-Innovative-Portfolio-Growth/default.aspx

Teva 2024 Results earnings conference call today at 8:00am ET, webcast and replay:
https://events.q4inc.com/attendee/899170090

* *NDA (New Drug Application): Formal request for approval to market a new pharmaceutical product, containing detailed data on its safety, efficacy, manufacturing, and labeling.*

About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.

medincell.com

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Chief Strategy Officer, U.S. Finance
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94